VALERITAS HOLDINGS COM (VLRX)

6.25
OTC Markets
Prev Close 6.25
Day Low/High 0.00 / 0.00
52 Wk Low/High 5.00 / 6.50
Exchange OTC Markets
Shares Outstanding 12.68B
Market Cap 79.24M
Div & Yield N.A. (N.A)

Latest News

V-Go® Data And Clinical Benefit Discussed During Panel Presentation On Insulin Therapy And Delivery At AADE 2016

V-Go® Data And Clinical Benefit Discussed During Panel Presentation On Insulin Therapy And Delivery At AADE 2016

Valeritas Demonstrates Ease of Use of V-Go Disposable Insulin Delivery Device to Attending Clinicians

Valeritas Announces Positive Results In Four Studies On V-Go® Disposable Insulin Delivery Device At ADA 2016

Valeritas Announces Positive Results In Four Studies On V-Go® Disposable Insulin Delivery Device At ADA 2016

Studies Demonstrate Clinical and Cost Benefit of V-Go

Valeritas Announces Retrospective Analysis Of The V-Go® Disposable Insulin Delivery Device Published Online In Drugs-Real World Outcomes, An International, Peer-Reviewed Journal

Valeritas Announces Retrospective Analysis Of The V-Go® Disposable Insulin Delivery Device Published Online In Drugs-Real World Outcomes, An International, Peer-Reviewed Journal

Data show that switching to V-Go for insulin delivery in a poorly controlled diabetes population at high risk results in significant glycemic improvement and payer cost savings

Valeritas Presents Positive Results Of Five Real-World Studies Of The V-Go® Disposable Insulin Delivery Device At AACE 2016

Valeritas Presents Positive Results Of Five Real-World Studies Of The V-Go® Disposable Insulin Delivery Device At AACE 2016

Results support previous findings that V-Go helps patients with diabetes improve glucose control while using less insulin

Valeritas Completes Alternative Public Offering And Raises Gross Proceeds Of $25.2 Million

Valeritas Completes Alternative Public Offering And Raises Gross Proceeds Of $25.2 Million

Funding Will Support Continued Commercialization of the V-Go® Disposable Insulin Delivery Device and Advance Next Generation Products

Tuesday's Health Winners & Losers

Valera takes off.

Indevus Buying Valera

It sees a strong urology focus.